The results in in-vivo models confirmed the hypothesis that YGS might inhibit tumor immune escape by sensitizing CRC stem cells via the NF-κB pathway through targeting TLR4, and YGS could inhibit the EMT process of CRC at the tissue level. The gene discussed is TLR4; the disease is colorectal carcinoma.